Cargando…

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

INTRODUCTION: The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary function (%FVC < 50%) of patients with idiopathic pulmonary fibrosis (IPF). However, there is no sufficient evidence in real world. OBJECTIVES: Reveal the utility and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abe, Mitsuhiro, Tsushima, Kenji, Sakayori, Masashi, Suzuki, Kenichi, Ikari, Jun, Terada, Jiro, Tatsumi, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186773/ https://www.ncbi.nlm.nih.gov/pubmed/30349191 http://dx.doi.org/10.2147/DDDT.S179427

Ejemplares similares

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Response to letter]
por: Abe, Mitsuhiro, et al.
Publicado: (2019)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
por: Sakayori, Masashi, et al.
Publicado: (2019)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
por: Abe, Mitsuhiro, et al.
Publicado: (2015)

An Analysis of the Clinical Benefit of 37 Bronchoalveolar Lavage Procedures in Patients with Hematologic Disease and Pulmonary Complications
por: Katsumata, Yusuke, et al.
Publicado: (2018)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
por: Koshikawa, Ken, et al.
Publicado: (2020)

Prognostic value of lymphocyte counts in bronchoalveolar lavage fluid in patients with acute respiratory failure: a retrospective cohort study
por: Hirasawa, Yasutaka, et al.
Publicado: (2021)

Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: Relationship with pulmonary function and clinical events
por: Suzuki, Masaki, et al.
Publicado: (2020)

Long‐term clinical course of idiopathic pulmonary haemosiderosis with rheumatoid arthritis
por: Sugimoto, Shunsuke, et al.
Publicado: (2016)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Corrigendum]
Publicado: (2019)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
por: Orsatti, Leticia, et al.
Publicado: (2019)

Feasibility and accuracy of rapid on-site evaluation of touch imprint cytology during transbronchial biopsy
por: Shikano, Kohei, et al.
Publicado: (2020)

End-tidal capnographic monitoring to detect apnea episodes during flexible bronchoscopy under sedation
por: Ishiwata, Tsukasa, et al.
Publicado: (2017)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study
por: Komatsu, Masamichi, et al.
Publicado: (2022)

What are the factors affecting the recovery rate of bronchoalveolar lavage fluid?
por: Shikano, Kohei, et al.
Publicado: (2021)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2017)

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone
por: Ipatova, Anastasia Y, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis
por: Nemoto, Masahiro, et al.
Publicado: (2021)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Tocilizumab-effective multicentric Castleman's disease with infiltration of eosinophil and IgG(4)-positive plasma cells: A case report
por: Katsumata, Yusuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pjivat32riq3th9mqf88jq4mbn